Cipla gains after receiving UK MHRA approval for Sereflo

Cipla rose 3.62% to Rs 580.50 at 15:15 IST on BSE after the company said it received a final approval for its lead MDI product Sereflo from UK's drug regulator.

The announcement was made during trading hours today, 23 December 2016.

Meanwhile, the BSE Sensex was up 57.91 points, or 0.22%, to 26,037.51.

On the BSE, so far 2.56 lakh shares were traded in the counter, compared with average daily volumes of 1.34 lakh shares in the past one quarter. The stock had hit a high of Rs 588.90 and a low of Rs 552.55 so far during the day.

The stock hit a 52-week high of Rs 660 on 29 December 2015. The stock hit a 52-week low of Rs 458.25 on 25 May 2016. The stock had outperformed the market over the past 30 days till 22 December 2016, rising 1.45% compared with the 0.28% fall in the Sensex. The scrip had also outperformed the market in past one quarter, falling 8.34% as against Sensex's 9.38% decline.

The large-cap company has equity capital of Rs 160.88 crore. Face value per share is Rs 2.

Cipla said it yielded a final approval for its lead MDI product Fluticasone + Salmeterol (Sereflo) from UK MHRA (UK Medicines and Healthcare products Regulatory Agency) for its partner in the UK. Sercflo, 25 mcg/125 mcg & 25 mcg/250 mcg are generic equivalent to GlaxoSmithKline's Seretide inhalers and are indicated for Asthma treatment.

Seretide Inhaler, for the aforementioned strengths, had UK sales of approximately $278 million for the 12 month period ending June 2016, according to IMS Health. Cipla's Sereflo will be launched in the UK through a partner in the coming weeks.

On a consolidated basis, Cipla's net profit dropped 34.75% to Rs 354.34 crore on 8.66% rise in net sales to Rs 3671.88 crore in Q2 September 2016 over Q2 September 2015.

Cipla is a global pharmaceutical company. Its portfolio includes over 1000 products across wide range of therapeutic categories with one quality standard globally.

Powered by Capital Market - Live News